Herbaria-Modern Botanicals Becomes the First Indian Skincare Brand to Debut at New York Fashion Week 2025

February 03, 2025 11:17 PM AEDT | By Businesswire India

Google News:

Image source: Businesswire India

Recent News

Energy and Resources Stocks Lead Divergence on ASX 200

ASX 200 slips as iron ore and gold miners retreat

Iron Ore Stocks Weigh on ASX 200 While Tech and Energy Rise

TD Cowen adds Gap to ’Best Smidcap Ideas’ list on brand momentum

Business Wire India
Herbaria-Modern Botanicals, India’s pioneering luxury vegan skincare brand, is making history as the first Indian skincare brand to be featured at New York Fashion Week (NYFW) from 6th February 2025. This landmark moment cements Herbaria’s position as a global innovator in clean beauty, bringing zero-plastic, high-performance botanical skincare to the world’s most influential fashion stage.

Founded by Gunjan Agnihotri & Raghav Bhatia, Herbaria-Modern Botanicals has rapidly gained recognition for its sensory-rich, sustainability-driven formulations that prove eco-conscious skincare can be luxurious, effective, and vibrant. From plant-based exfoliants to fruit-infused shower butters, Herbaria redefines beauty with its bold philosophy: “Sustainability is not boring.”

From India to New York: A Breakthrough for Clean Beauty

New York Fashion Week has long been the epicenter of cutting-edge beauty trends, and Herbaria’s inclusion marks a major milestone for the Indian beauty industry. As the brand will provide backstage skin prep for models, reinforcing the importance of skin-first beauty in high-fashion aesthetics. Herbaria is the - exclusive beauty gift bag partner - to NYFW.

"Being the first Indian skincare brand at NYFW is not just a win for us—it’s a win for Indian innovation in the global beauty space. We are here to prove that high-performance skincare can be sustainable, sensorial, and absolutely stunning," said Gunjan Agnihotri & Raghav Bhatia, Founders of Herbaria-Modern Botanicals.

The Future of Indian Skincare on a Global Stage

Herbaria’s debut at NYFW 2025 aligns with the brand’s mission to elevate Indian beauty expertise on an international level. With a commitment to 100% vegan formulations, plastic-free packaging, and powerful botanical actives, Herbaria is setting a new standard for luxury skincare—one that resonates with conscious consumers worldwide.

As the brand prepares to take center stage at one of the world’s most prestigious fashion events, this milestone signals a new era for Indian beauty brands in the global market.

Website: www.herbaria.co.in
Instagram: @herbaria.modernbotanicals

About Herbaria-Modern Botanicals

Herbaria-Modern Botanicals is an Indian luxury vegan skincare brand dedicated to creating high-performance, sustainable, and sensory-rich beauty experiences. With zero-plastic packaging and plant-powered formulations, Herbaria champions clean, conscious, and effective skincare. Available online globally and in select stores across India, the brand is redefining beauty—one innovative product at a time.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Healius (ASX:HLS) Sees IVD Growth Momentum in Australia Healthcare Landscape
18, June, 2025
ASX200 Biotech Player Imugene (ASX:IMU) Strengthens US IP Position with Key Patent Grant
18, June, 2025
Biotech Firm Tetratherix (TTX) Sets ASX Listing Date Amid Expansion Drive
18, June, 2025
Mayne Pharma Shareholders Endorse $672M Cosette Deal as ASX200 Court Clash Looms
18, June, 2025
Neuren Pharmaceuticals Sees ASX200 Momentum as Market Eyes EMA Approval
18, June, 2025
Cochlear’s New Tech Sparks Market Enthusiasm as ASX200 Giant Targets Global Growth
18, June, 2025
Pro Medicus (ASX:PME) Strengthens Position in Radiology Software Sector | ASX 200
17, June, 2025
4DMedical (ASX:4DX) Expands Stanford Partnership, Strengthening ASX300 Medical Imaging Innovation
17, June, 2025
Recce Pharmaceuticals (ASX:RCE) Strengthens Clinical Pipeline via Avenue Capital Deal | ASX 200
17, June, 2025
CSL (ASX:CSL) Advances in ASX300 with FDA Nod for Innovative HAE Therapy
17, June, 2025

View All

Markets

Related Articles

Sponsored Articles

1

2

3

4

5

Investing Ideas

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27